190 completed, 34 unknown, 16 terminated, 10 recruiting. 273 Phase 3, 72 Phase 2.
Follow Insulin Resistance: new trials by email Literature Review of Insulin Resistance trials Research Report on Insulin Resistance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2 / Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 226 | 2027-09-01 | 2026-09-28 |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 600 | 2026-12-01 | 2026-08-18 |
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1500 | 2026-10-28 | 2026-11-02 |
| Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-09-01 | 2025-12-18 | |
| Exercise and Intranasal Insulin in Type 2 Diabetes Intranasal Insulin, Intranasal Placebo, High Intensity Exercise - Type 2 Diabetes, Insulin Sensitivity/Resistance | Phase 2 / Phase 3 | Recruiting | Rutgers, The State University of New Jersey | 60 | 2026-08-03 | 2026-06-30 |
| Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) Galantamine Hydrobromide Extended Release - Spinal Cord Injury, Traumatic Spinal Cord Injury | Phase 2 / Phase 3 | Recruiting | Northwell Health | 60 | 2026-06-15 | 2026-06-04 |
| No Guts No Glory Probiotics Probiotic Formula, Placebo - Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine | Phase 2 / Phase 3 | Recruiting | University Medical Center Groningen | 112 | 2026-06-01 | 2026-05-26 |
| Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes tributyrin, Placebo - Diabete Mellitus | Phase 3 | Not yet recruiting | Ain Shams University | 60 | 2026-03-26 | 2026-03-31 |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo - Lipidemia, Type 2 Diabetes (T2DM) | Phase 3 | Active not recruiting | NewAmsterdam Pharma | 300 | 2025-12-11 | 2026-09-09 |
| Semaglutide Treatment in Type 1 Diabetes Semaglutide 2.4mg, Semaglutide placebo - Obesity in Diabetes, Obesity/Therapy | Phase 3 | Not yet recruiting | Nordsjaellands Hospital | 122 | 2025-10-01 | 2025-08-08 |
| Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor Empagliflozin (oral), Matching placebo - Metabolic Syndrome | Phase 3 | Enrolling by invitation | The University of Hong Kong | 160 | 2025-08-13 | 2025-08-24 |
| Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI) Metformin, Placebo - Obesity and Cardiovascular Risk, Insulin Resistance | Phase 3 | Recruiting | University Of Nigeria Teaching Hospital | 220 | 2025-07-23 | 2025-12-22 |
| Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment., A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC - Metabolic Syndrome, Cardiovascular Disease (CKD) | Phase 3 | Enrolling by invitation | Guangdong Provincial Hospital of Traditional Chinese Medicine | 530 | 2025-04-24 | 2025-06-13 |
| A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes Intervention Period 1: Semaglutide + Empagliflozin, Intervention Period 2: Semaglutide + Empagliflozin Placebo, Intervention Period 3: Semaglutide Placebo + Empagliflozin - Diabetes Type 1 | Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 36 | 2025-04-01 | 2025-03-30 |
| Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. Turmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day - Cognitive Decline, Subjective Cognitive Impairment | Phase 2 / Phase 3 | Active not recruiting | Instituto Mexicano del Seguro Social | 100 | 2025-02-20 | 2026-03-25 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin GZR4, Insulin Glargine U100 group - Diabetes | Phase 3 | Active not recruiting | Gan & Lee Pharmaceuticals. | 580 | 2025-02-18 | 2025-11-25 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM) GZR4, Insulin Glargine U100 - Diabetes | Phase 3 | Active not recruiting | Gan & Lee Pharmaceuticals. | 580 | 2025-02-17 | 2025-11-28 |
| A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin GZR4, insulin degludec - Diabetes | Phase 3 | Active not recruiting | Gan & Lee Pharmaceuticals. | 620 | 2025-02-15 | 2025-11-21 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
Showing 20 of 273. Sign in to see all of them.
Metabolic Syndrome (105) · Diabetes Mellitus, Type 2 (59) · Diabetes Mellitus (50) · Obesity (46) · Diabetes Mellitus, Type 1 (24) · Hyperglycemia (13) · Inflammation (13) · Cardiovascular Diseases (12) · Hypertension (12) · Glucose Intolerance (11) · Overweight (11) · Dyslipidemias (10) · Weight Loss (10) · Prediabetic State (9)
Nutritional and Metabolic Diseases (273) · Glucose Metabolism Disorders (272) · Hyperinsulinism (272) · Metabolic Diseases (268) · Endocrine System Diseases (135) · Pathological Conditions, Signs and Symptoms (83) · Diabetes Mellitus (70) · Signs and Symptoms (60) · Body Weight (54) · Nutrition Disorders (54) · Overnutrition (52) · Overweight (41) · Pathologic Processes (35) · Vascular Diseases (34)
Metformin (36) · Insulin (18) · Insulin Glargine (12) · Exercise (9) · Pioglitazone (8) · Rosiglitazone (7) · semaglutide (7) · empagliflozin (6) · Atorvastatin (5) · Insulin Lispro (5) · Liraglutide (5) · 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine (4) · Biguanides (4) · Diet (4) · Insulin Aspart (4)
Ain Shams University (5) · AstraZeneca (5) · Brigham and Women's Hospital (5) · Sanofi (5) · Tanabe Pharma Corporation (5) · Geropharm (4) · Massachusetts General Hospital (4) · McGill University Health Centre/Research Institute of the McGill University Health Centre (4) · Population Health Research Institute (4) · University of Colorado, Denver (4) · University of Erlangen-Nürnberg Medical School (4) · Catalysis SL (3) · Chinese Academy of Sciences (3) · Emory University (3) · Gan & Lee Pharmaceuticals. (3)
United States (65) · Canada (35) · Mexico (19) · Germany (16) · Italy (16) · China (13) · France (11) · Japan (11) · Australia (10) · Netherlands (9) · Denmark (8) · Spain (8) · United Kingdom (8) · Egypt (7) · Russia (7)
Kazuoki Kondo, MD (5) · Takashi Kadowaki, Professor (4) · Allison B. Goldfine, MD (3) · Steven J Russell, MD, PhD (3) · Xu Lin, MD, PhD (3) · David C Klonoff, M.D., F.A.C.P. (2) · Dick C Chan, PhD (2) · Francesco Squadrito, MD (2) · Guillermo Umpierrez, MD (2) · Hertzel Gerstein, MD (2) · Jia Lu, PhD (2)
PMID 20826632, PMID 24281606, PMID 31956422, PMID 32275191, PMID 37526194, PMID 11347758, PMID 11527911, PMID 12037147, PMID 1244564, PMID 14583175, PMID 14688154, PMID 15855569, PMID 16043738, PMID 16504835, PMID 16614616, PMID 16627388, PMID 16636217, PMID 16784922, PMID 17206944, PMID 17245174, PMID 17337495, PMID 17387446, PMID 17416370, PMID 17563348, PMID 17583798, PMID 17980364, PMID 18068166, PMID 18364705, PMID 18406632, PMID 18509206, PMID 18671796, PMID 19056992, PMID 19092145, PMID 19116237, PMID 19156626, PMID 19321570, PMID 19655124, PMID 19720420, PMID 19726779, PMID 19841045, PMID 19898642, PMID 20019677, PMID 20092585, PMID 20204386, PMID 20231565, PMID 20484482, PMID 20524974, PMID 20573639, PMID 20671408, PMID 20718771
2005 (3), U01DK074556 (2), 1RC1DK086132 (1), 2008 (1), 2009 (1), 2015 (1), 2025 (1), 5UL1TR000135 (1), F32DK068902 (1), KL2TR000136 (1), P50HL083813 (1), R00HD060762 (1), R01AG018198 (1), R01AG020076 (1), R01AG064951 (1)